Atria Investments LLC lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 7.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 50,867 shares of the company’s stock after acquiring an additional 3,647 shares during the period. Atria Investments LLC’s holdings in Johnson & Johnson were worth $6,519,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds have also recently made changes to their positions in JNJ. NuWave Investment Management LLC bought a new stake in Johnson & Johnson in the 4th quarter worth approximately $680,000. IBM Retirement Fund grew its position in Johnson & Johnson by 4.8% in the 4th quarter. IBM Retirement Fund now owns 70,094 shares of the company’s stock worth $10,697,000 after purchasing an additional 3,221 shares during the period. Keeler Thomas Management LLC bought a new stake in Johnson & Johnson in the 4th quarter worth approximately $2,692,000. OxFORD Asset Management LLP grew its position in Johnson & Johnson by 407.9% in the 3rd quarter. OxFORD Asset Management LLP now owns 27,431 shares of the company’s stock worth $3,561,000 after purchasing an additional 22,030 shares during the period. Finally, Hefty Wealth Partners grew its position in Johnson & Johnson by 959.3% in the 4th quarter. Hefty Wealth Partners now owns 6,970 shares of the company’s stock worth $974,000 after purchasing an additional 6,312 shares during the period. 65.97% of the stock is owned by institutional investors.
Get Johnson & Johnson alerts:Johnson & Johnson opened at $121.34 on Monday, according to Marketbeat. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.25 and a current ratio of 1.58. Johnson & Johnson has a fifty-two week low of $118.62 and a fifty-two week high of $148.32. The firm has a market cap of $325.54 billion, a P/E ratio of 16.62, a PEG ratio of 1.86 and a beta of 0.73.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 17th. The company reported $2.06 earnings per share for the quarter, beating analysts’ consensus estimates of $2.00 by $0.06. Johnson & Johnson had a net margin of 1.58% and a return on equity of 30.65%. The company had revenue of $20.01 billion for the quarter, compared to analysts’ expectations of $19.50 billion. During the same quarter in the previous year, the company earned $1.83 EPS. Johnson & Johnson’s revenue for the quarter was up 12.6% on a year-over-year basis. equities analysts expect that Johnson & Johnson will post 8.13 earnings per share for the current year.
The company also recently announced a quarterly dividend, which was paid on Tuesday, June 12th. Investors of record on Tuesday, May 29th were paid a dividend of $0.90 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $0.84. The ex-dividend date of this dividend was Friday, May 25th. This represents a $3.60 dividend on an annualized basis and a dividend yield of 2.97%. Johnson & Johnson’s payout ratio is 49.32%.
JNJ has been the subject of a number of research analyst reports. Jefferies Financial Group set a $161.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a research report on Friday, March 23rd. Vetr downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating and set a $124.55 target price for the company. in a research report on Monday, March 26th. TheStreet downgraded shares of Johnson & Johnson from an “a” rating to a “c+” rating in a research report on Monday, March 26th. Zacks Investment Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $143.00 target price for the company in a research report on Wednesday, March 28th. Finally, Morgan Stanley cut their target price on shares of Johnson & Johnson from $148.00 to $143.00 and set an “equal weight” rating for the company in a research report on Tuesday, April 10th. Six investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and ten have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $141.60.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
No comments:
Post a Comment